Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entera Bio Ltd.ENTX · Entity 5464 | Chief Medical Officer | April 24, 2023 | April 25, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entera Bio Ltd.
Report date April 24, 2023 · Filed April 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2033-04-24 | Direct | 35,000 |
Reported balance
After 2023-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-24 · Grant · Acquired 35,000 · Balance 35,000 F1: The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2023 Filed Apr 25, 2023 21:21 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001178913-23-001532 · ownership.xml · derivative · entry 1 Santora Arthur C II · CIK 0001904746 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,000 shares Expires 2033-04-24 F1 · derivative.exercise_date: The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:09 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001178913-22-003374 · ownership.xml · derivative · entry 1 Santora Arthur C II · CIK 0001904746 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 20,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.